CY1117273T1 - Υγρη φαρμακευτικη συνθεση η οποια περιεχει νιτισινονη - Google Patents

Υγρη φαρμακευτικη συνθεση η οποια περιεχει νιτισινονη

Info

Publication number
CY1117273T1
CY1117273T1 CY20161100186T CY161100186T CY1117273T1 CY 1117273 T1 CY1117273 T1 CY 1117273T1 CY 20161100186 T CY20161100186 T CY 20161100186T CY 161100186 T CY161100186 T CY 161100186T CY 1117273 T1 CY1117273 T1 CY 1117273T1
Authority
CY
Cyprus
Prior art keywords
liquid pharmaceutical
nitisinone
pharmaceutical composition
composition containing
nititinone
Prior art date
Application number
CY20161100186T
Other languages
English (en)
Inventor
Lennart Svensson
Hans Sidén
Original Assignee
Swedish Orphan Biovitrum International Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum International Ab filed Critical Swedish Orphan Biovitrum International Ab
Publication of CY1117273T1 publication Critical patent/CY1117273T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αναφέρεται σε υγρή φαρμακευτική τυποποίηση κατάλληλη για στοματική χορήγηση, η οποία περιέχει εναιώρημα αποτελεσματικής ποσότητας μικροκατανεμημένης 2-(2-νιτρο-4-τριφθορο-μεθυλβενζοϋλ)-1,3-κυκλοεξανοδιόνης (νιτισινόνης) και ρυθμιστικό κιτρικού οξέος το οποίο έχει pΗ εντός της διακύμανσης 2,5 έως 3,5. Η τυποποίηση είναι χρήσιμη στη θεραπεία διαταραχών και παθήσεων στις οποίες είναι επιθυμητή η αναστολή της 4-υδροξυφαινυλοπυρουβικής διοξυγονάσης (HPPD), π.χ. σε κληρονομική τυροσιναιμία τύπου I.
CY20161100186T 2011-06-23 2016-03-03 Υγρη φαρμακευτικη συνθεση η οποια περιεχει νιτισινονη CY1117273T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1150585 2011-06-23
EP12802262.1A EP2723320B1 (en) 2011-06-23 2012-06-20 Liquid pharmaceutical composition comprising nitisinone

Publications (1)

Publication Number Publication Date
CY1117273T1 true CY1117273T1 (el) 2017-04-26

Family

ID=47422827

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100186T CY1117273T1 (el) 2011-06-23 2016-03-03 Υγρη φαρμακευτικη συνθεση η οποια περιεχει νιτισινονη

Country Status (22)

Country Link
US (2) US9301932B2 (el)
EP (1) EP2723320B1 (el)
JP (1) JP6038132B2 (el)
CN (1) CN103747781B (el)
AU (1) AU2012273515B2 (el)
BR (1) BR112013033008B1 (el)
CA (1) CA2838039C (el)
CL (1) CL2013003630A1 (el)
CY (1) CY1117273T1 (el)
DK (1) DK2723320T3 (el)
ES (1) ES2566787T3 (el)
HR (1) HRP20160286T1 (el)
HU (1) HUE027304T2 (el)
IL (1) IL229677A (el)
MX (1) MX2013014567A (el)
PL (1) PL2723320T3 (el)
RS (1) RS54632B1 (el)
RU (1) RU2605301C2 (el)
SI (1) SI2723320T1 (el)
SM (1) SMT201600097B (el)
UA (1) UA110979C2 (el)
WO (1) WO2012177214A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012273515B2 (en) * 2011-06-23 2016-11-03 Swedish Orphan Biovitrum International Ab Liquid pharmaceutical composition comprising nitisinone
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations
BR112016024756A2 (pt) * 2014-04-30 2017-08-15 Swedish Orphan Biovitrum Int Ab regimes de dosagem de nitisinona para o tratamento da alcaptonúria
CN104623428A (zh) * 2015-03-13 2015-05-20 庄彩梅 一种缓解遗传性酪氨酸血症的中药制剂及其制备方法
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
ITUB20160972A1 (it) * 2016-02-23 2017-08-23 Univ Degli Studi Di Siena Trattamento dell’alkaptonuria e della tirosinemia di tipo 1
CN110464716A (zh) * 2019-09-03 2019-11-19 黄嘉若 一种尼替西农在制备治疗肺癌药物中的用途
CN112107548A (zh) * 2020-10-30 2020-12-22 兆科药业（广州）有限公司 一种含有尼替西农的药物组合物及其制备方法
CN114831974A (zh) * 2022-06-23 2022-08-02 徐州医科大学 尼替西农在制备预防和治疗内毒素性休克疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006158A (en) 1984-12-20 1991-04-09 Ici Americas Inc. Certain 2-(2-substituted benzoyl)-1,3-cyclohexanediones
US4695673A (en) 1985-11-20 1987-09-22 Stauffer Chemical Company Process for the production of acylated 1,3-dicarbonyl compounds
DE69228813T2 (de) * 1991-06-24 1999-08-05 Zeneca Ltd Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
US5668089A (en) 1996-04-08 1997-09-16 Zeneca Limited Selective corn herbicide
AU2003249741A1 (en) * 2002-07-03 2004-01-23 Hartmut M. Hanauske-Abel Methods of inhibiting 4-hydroxyphenylpyruvate dioxygenase in a living system
GB0405760D0 (en) 2004-03-15 2004-04-21 Syngenta Participations Ag Agrochemical formulation
GB0414895D0 (en) 2004-07-02 2004-08-04 Syngenta Ltd Herbicidal formulation
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
US20100305095A1 (en) 2006-08-18 2010-12-02 Kim Zachary Travis Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs
CA2742841A1 (en) * 2008-11-06 2010-05-14 Biotie Therapies, Inc. Treatment of restless leg syndrome and sleep disorders
US8354451B2 (en) * 2009-03-09 2013-01-15 The Uwm Research Foundation, Inc. Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase
AU2012273515B2 (en) * 2011-06-23 2016-11-03 Swedish Orphan Biovitrum International Ab Liquid pharmaceutical composition comprising nitisinone
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations

Also Published As

Publication number Publication date
SMT201600097B (it) 2016-04-29
BR112013033008B1 (pt) 2021-05-18
HRP20160286T1 (hr) 2016-05-06
MX2013014567A (es) 2014-08-21
AU2012273515A1 (en) 2013-12-12
BR112013033008A8 (pt) 2018-03-06
CL2013003630A1 (es) 2014-11-21
US20140206771A1 (en) 2014-07-24
AU2012273515B2 (en) 2016-11-03
RS54632B1 (en) 2016-08-31
NZ618332A (en) 2015-06-26
SI2723320T1 (sl) 2016-05-31
JP6038132B2 (ja) 2016-12-07
PL2723320T3 (pl) 2016-06-30
EP2723320B1 (en) 2016-01-13
UA110979C2 (uk) 2016-03-10
WO2012177214A1 (en) 2012-12-27
DK2723320T3 (en) 2016-03-21
HUE027304T2 (en) 2016-10-28
BR112013033008A2 (pt) 2017-01-31
EP2723320A1 (en) 2014-04-30
JP2014517067A (ja) 2014-07-17
US9301932B2 (en) 2016-04-05
CN103747781A (zh) 2014-04-23
IL229677A0 (en) 2014-01-30
IL229677A (en) 2017-03-30
RU2605301C2 (ru) 2016-12-20
RU2014101990A (ru) 2015-07-27
CN103747781B (zh) 2018-06-08
CA2838039A1 (en) 2012-12-27
US20150174081A1 (en) 2015-06-25
CA2838039C (en) 2017-10-24
ES2566787T3 (es) 2016-04-15
EP2723320A4 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
CY1117273T1 (el) Υγρη φαρμακευτικη συνθεση η οποια περιεχει νιτισινονη
ECSP12012353A (es) Compuestos, composiciones de tioacetato y métodos de uso
NI201500167A (es) Compuestos químicos
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
EA201400533A1 (ru) Жидкая антимикробная очищающая композиция для твердых поверхностей
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BR112015008987A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
DOP2015000170A (es) Compuestos químicos
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112015027477A8 (pt) bolus, seus usos, e kit
BR112015008849A2 (pt) composições estáveis contendo perácido
BR112015023761A2 (pt) moduladores de molécula pequena de pcsk9 e seus métodos e usos
EA201400535A1 (ru) Индивидуальная композиция для очищения
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
EA201391304A1 (ru) 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке
IT1404171B1 (it) Composizione per l'uso nel trattamento dei problemi/disturbi della menopausa e nel trattamento dell'invecchiamento generale dell'organismo
BR112015014262A2 (pt) formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, método de tratamento de rinite alérgica, uso de uma formulação farmacêutica, e, método para o tratamento de condição inflamatória e/ou alérgica